Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Impurities & degradation products

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present.

704 FDA drug recalls with this cause, newest first.

Every drug has a specification for how much of each impurity or breakdown product it may contain. These recalls are lots that exceeded one of those limits - often a related compound formed during manufacturing or storage, or an out-of-specification result found during routine stability testing. Nitrosamine impurities are common enough to get their own category; everything else lands here.

Class II · Moderate risk

Glycopyrrolate Tabs

Failed Impurities/Degradation Specification: High Out of Specification Results for Individual Unknown Impurity.

Terminated Impurity / degradation NCS Healthcare of Kentucky Inc NDC 0615-8170-39 D-0850-2020
Class II · Moderate risk

Dutasteride Capsules

Failed Impurities/Degradation Specifications: High out of specification results for related compounds.

Terminated Impurity / degradation AVKARE Inc. NDC 50268-282-13 D-0661-2020
Class II · Moderate risk

Sumatriptan Succinate Tablets

Failed Impurities/Degradation Specifications; out-of-specification results obtained for related substance.

Terminated Impurity / degradation Sun Pharmaceutical Industries, Inc. D-0660-2020
Class II · Moderate risk

Sumatriptan Succinate Tablets

Failed Impurities/Degradation Specifications; out-of-specification results obtained for related substance.

Terminated Impurity / degradation Sun Pharmaceutical Industries, Inc. NDC 62756-521-69 D-0659-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.

Terminated Impurity / degradation Asclemed USA Inc. dba Enovachem Pharmaceuticals D-0652-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.

Terminated Impurity / degradation Asclemed USA Inc. dba Enovachem Pharmaceuticals D-0651-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.

Terminated Impurity / degradation Asclemed USA Inc. dba Enovachem Pharmaceuticals D-0650-2020
Class II · Moderate risk

Estriol

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation Medisca, Inc. D-0622-2020
Class III · Low risk

Isotretinoin Capsules

Failed Impurities/Degradation Specifications: Tretinoin levels slightly above specification limits.

Terminated Impurity / degradation Amneal Pharmaceuticals, Inc. NDC 69238-1174-3 D-0321-2020
Class II · Moderate risk

Rifampin for Injection

Failed Impurities/Degradation Specifications: discoloration due to elevated unknown impurity results which could decrease the effectiveness of the product.

Terminated Impurity / degradation Mylan Laboratories Limited (Sterile Products Division) NDC 67457-445-60 D-0139-2020
Class II · Moderate risk

Anagrelide Capsules

Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.

Terminated Impurity / degradation Torrent Pharma Inc. NDC 13668-453-01 D-1862-2019
Class II · Moderate risk

Allergy Relief

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation Aurolife Pharma, LLC NDC 49035-995-62 D-1869-2019
Class II · Moderate risk

Allergy Relief

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation Aurolife Pharma, LLC NDC 46122-387-23 D-1866-2019